Jacobio receives RMB125m upfront payment to advance oncology therapies

Jacobio Pharmaceuticals Group Co., Ltd. today announced the receipt of an RMB125 million upfront payment from Oceanpine Capital. This payment is in connection with the Capital Increase Agreement and Equity Transfer Agreement, as previously announced on October 15, 2025.

The payment was received by Beijing Jacobio, an indirect non-wholly owned subsidiary of the company. This financial injection is expected to significantly enhance the Group's cash reserves, thereby supporting the continued development of its pipeline of innovative oncology therapies.

Jacobio is dedicated to developing new products for patient health, with a focus on targeted oncology and tumor immunotherapy, including pipelines in KRAS, Sting, P53, and MYC pathways. The company's R&D centers are located in Beijing, Shanghai, and Boston.